Morimatsu International Holdings Company Limited (HK:2155) has released an update.
Morimatsu International Holdings Company Limited has announced the implementation of a Share Incentive Scheme by its wholly-owned subsidiary, Morimatsu Pharmaceutical, following shareholder approval. The scheme will involve a capital contribution that grants approximately 14.91% of Morimatsu Pharmaceutical’s registered capital to incentive participants, resulting in the subsidiary becoming a non-wholly owned entity of the company. This move, classified as a discloseable transaction, aligns with the company’s strategy to enhance value and promote shared growth between the subsidiary and its contributors.
For further insights into HK:2155 stock, check out TipRanks’ Stock Analysis page.